(600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 600276 · · 11 pages · Chinese
Jiangsu Hengrui Pharmaceuticals Co., Ltd. on 6ix
Earlier from Jiangsu Hengrui Pharmaceuticals
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Receipt of the Drug Clinical Trial Approval Notice
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Progress in Repurchasing A-Shares
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Indicative Announcement on Acceptance by the EMA of the Application for Drug Marketing Authorization
- Jiangsu Hengrui Pharmaceuticals: Hengrui Pharma Announces EMA Validation of Marketing Authorisation Application for Wevdury (fuzuloparib) in Combination with Abiraterone for Metastatic Castration-Resistant Prostate Cancer
- Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596
Later from Jiangsu Hengrui Pharmaceuticals
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Indicative Announcement on Acceptance of Application for Drug Marketing Authorization and Inclusion in the Priority Review Program
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Resolutions of the 6th Meeting of the 10th Board of Directors
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Indicative Announcement on FDA Acceptance of the Resubmitted Biologics License Application for Camrelizumab for Injection
- Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026
Follow Jiangsu Hengrui Pharmaceuticals into a list and get an email when it puts out news.
Follow Jiangsu Hengrui Pharmaceuticals